Compare OGE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OGE | PRAX |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 9.6B |
| IPO Year | 2009 | 2020 |
| Metric | OGE | PRAX |
|---|---|---|
| Price | $49.37 | $327.15 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 15 |
| Target Price | $47.33 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.5M | 375.4K |
| Earning Date | 05-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 5.94 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $3,260,100,000.00 | N/A |
| Revenue This Year | $2.45 | N/A |
| Revenue Next Year | $0.96 | $1,840.20 |
| P/E Ratio | $21.16 | ★ N/A |
| Revenue Growth | ★ 9.21 | N/A |
| 52 Week Low | $40.80 | $26.70 |
| 52 Week High | $49.18 | $354.87 |
| Indicator | OGE | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 83.40 | 53.37 |
| Support Level | $42.94 | $290.36 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 1.02 | 18.77 |
| MACD | 0.28 | -1.12 |
| Stochastic Oscillator | 97.05 | 55.40 |
OGE Energy is a holding company for Oklahoma Gas & Electric, a regulated utility with electricity generation, transmission, and distribution service for 900,000 customers in Oklahoma and western Arkansas. In December 2021, OGE divested its 25.5% stake in Enable Midstream Partners, an oil and gas services company it created in 2013 through a unit exchange merger with Energy Transfer. OGE sold its 95.4 million limited partner units of Energy Transfer throughout 2022. OGE sold its retail gas business in 1928 and no longer has any gas operations.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.